Table 1 Patient characteristics at baselinea
Characteristic | N = 15 |
|---|---|
Sex: n (%) | |
Female | 14 (93.3) |
Male | 1 (6.7) |
Age: median (range) | |
Age at baseline (years) | 69 (30–76) |
ECOG performance status: n (%) | |
ECOG 0 | 9 (60) |
ECOG 1 | 6 (40) |
Presence of neurological symptoms at baseline: n (%) | |
Yes | 6 (40) |
No | 9 (60) |
Disease subtype: n (%) | |
HER2-positive/luminal B | 12(80) |
HER2-positive/nonluminal | 3 (20) |
Disease stage at primary diagnosis: n (%) | |
Stage IV | 10 (66.7) |
Stage I–III | 5 (33.3) |
Brain metastasis-free survival (BMFS): median (range) | |
BMFS from diagnosis of metastatic disease (months) | 17 (0-48) |
Brain-only disease: n (%) | |
Yes | 2 (13.3) |
No | 13 (86.7) |
Visceral metastases: n (%) | |
Yes | 12 (80) |
No | 3 (20) |
GPA indexb at baseline: n (%) | |
GPA 2.5 | 3 (20) |
GPA 3.0 | 11 (73.3) |
GPA 3.5 | 1 (6.7) |
Previous HER2-directed therapy: n (%) | |
Trastuzumab + pertuzumab | 15 (100) |
T-DM1 | 9 (60) |
Lapatinib | 4 (26.7) |
Other | 1 (6.7) |
Status of brain metastases; n (%) | |
Untreated | 6 (40) |
Primary brain metastases after previous local therapy | 9 (60) |
Type of previous local therapy for brain metastases: n (%) | |
WBRT | 3 (20) |
WBRT + SRT/SRS and/or neurosurgery | 3 (20) |
SRT/SRS | 3 (20) |
Time from last previous local intervention to inclusion: median (range) | |
Time from last local treatment (months) | 13 (5–65) |
Previous lines of treatment for metastatic breast cancer: median (range) | |
Number of previous lines of treatment before trastuzumab deruxtecan | 2 (1–5) |
